Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Ridaforolimus - Medinol

Next Previous
X
Search
Drug Profile

Ridaforolimus - Medinol

Alternative Names: AP 23573; BioNIR; Deforolimus; EluNIR; EluNIR™ Ridaforolimus-Eluting Coronary Stent System; Jenzyl; MedJ-01; MK-8669; NirSupreme

Latest Information Update: 05 Nov 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator ARIAD Pharmaceuticals
  • Developer ARIAD Pharmaceuticals; Medinol; Merck & Co
  • Class Antineoplastics; Macrolides; Vascular disorder therapies
  • Mechanism of Action MTOR protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Sarcoma
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase III Coronary artery restenosis
  • Preregistration Submission Withdrawal Sarcoma
  • Discontinued Breast cancer; Cancer; Endometrial cancer; HER2 positive breast cancer; Neurodegenerative disorders; Non-small cell lung cancer; Ovarian cancer; Prostate cancer; Renal cell carcinoma; Solid tumours

Most Recent Events

  • 06 Oct 2023 Medinol plans a clinical trial for Coronary artery restenosis (Intra-arterial) in February 2024 (NCT06071702)
  • 24 Mar 2023 Medinol completes a phase III trial in Coronary artery restenosis in Japan (Intra-arterial) (NCT02828917)
  • 14 Apr 2021 Phase III development is still ongoing in Israel, Belgium, Canada, Italy, Netherlands, Poland, Japan, USA and Spain

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top